Eli Lilly & Co. (LLY) Tops Q4 EPS by 39c, Revenues Beat; Offers FY21 EPS/Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Eli Lilly & Co. (LLY) Tops Q4 EPS by 39c, Revenues Beat; Offers FY21 EPS/Revenue Guidance

Lilly (LLY) and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate

January 28, 2021 6:40 AM EST

Eli Lilly and Company (NYSE: LLY) and Asahi Kasei Pharma Corporation today announced a license agreement whereby Lilly will acquire the exclusive rights for AK1780 from Asahi Kasei Pharma. AK1780 is an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending dose and clinical pharmacology studies. P2X7 receptors have been consistently implicated in neuroinflammation, a driving force in chronic pain conditions.

Under the terms of the agreement, Lilly will be responsible... More